RapportRx is a healthcare technology company that specializes in providing patient support services and solutions to improve medication adherence and patient outcomes. The company leverages data analytics, patient engagement strategies, and a deep understanding of the patient journey to offer personalized support and interventions.

RapportRx

NextGen Life Sciences provides solutions in the fields of biotechnology and healthcare by offering testing equipment, reagents, kits, and instruments for medical research.

NextGen Life Sciences

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

Rapport Therapeutics

Our CEO, Abraham (Abe) Ceesay, participated in a fireside chat at the first ever Boston While Black (BWB) Biotech & Life Sciences industry mixer held at Entrada Therapeutics at the end of #BlackHistoryMonth. There, he was able to share insights from his own experiences navigating his career journey in the world of #BostonBiotech with an audience of early to executive-level Black professionals.  Thank you to BWB for the opportunity!

This morning, we announced the appointment of Kathy Wilkinson as Chief People Officer. Kathy joins us with over 20 years of human resource experience in the #biopharma world. As Rapport continues to grow, Kathy will be invaluable to shaping our people and patient focused culture. We are thrilled to welcome you aboard, Kathy!  
 

We are pleased to share that the National Institute of Neurological Disorders and Stroke (NINDS) has granted Rapport acceptance into the Preclinical Screening Platform for Pain (PSPP) program, which evaluates assets for novel #pain #therapeutics through preclinical studies. This is a tremendous honor and further validates the direction we’re taking with our scientific approach. Learn more about the PSPP program on the NINDS website here: http://bit.ly/492H23x

Today, we celebrate International Day of Women and Girls in Science, a day to reflect on the accomplishments of women in science everywhere and shine the spotlight on the ever-present need to support women and girls in their pursuit of STEM careers. We are humbled at Rapport to have incredible women colleagues who are beacons of strength and inspiration for the next generation of scientists. 
 
#WomenInScience #IDWGS #InternationalDayofWomenandGirlsinScience #WomenInSTEM

A warm welcome to Brian Corcoran who has joined our team as Controller. In this role, Brian will be responsible for all accounting procedures, processes, and financial reporting, as well as leading accounting teams. He will also partner with the management team on building financial infrastructure and policies that will support the company’s growth.
 
Glad to have you on the team, Brian!

Metric
Company Name	RapportRx	NextGen Life Sciences
Symbol
MSH ID	COM:RAPPORTRX	COM:NEXTGENLIFE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare Technology	Biotechnology
Country	US	IN
Stage
Employee Count	49
Website	rapportrx.com	nextgenlife.com
LinkedIn	rapport-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RAPPORTRX

RapportRx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue